AVADEL PHARMACEUTICALS PLC — Director's Dealing 2019

Aug 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2019-08-07

Reporting Person: Ende Eric J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-07	Stock Option (right to buy)	$2.03	A	60000	Acquired	2029-08-07	ADSs (60000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
ADSs	27900	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.49	2029-05-22	ADSs (8057)	8057	Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 01/31/2019; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.

F3: Options are exercisable as to 2,685 shares, 2,686 shares and 2,686 shares on May 22, 2020, May 22, 2021 and May 22, 2022, respectively.

F4: Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.